Eisai

Eisai bites back against restricted coverage plan for Aduhelm
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Eisai
Biogen
Aduhelm
Alzheimer's disease
FDA
CMS
Flag link:
7 drugs likely to hit $1B in annual revenue in the next 5 years
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
Flag link:
Biogen and Eisai move forward with investigational Alzheimer's therapy
Biogen and Eisai move forward with investigational Alzheimer's therapy
Biopharma Reporter
Biogen
Eisai
lecanemab
Alzheimer's disease
fast track
FDA
Flag link:
Biopharma developments over the Christmas period
Biopharma developments over the Christmas period
EP Vantage
Alnylam Pharmaceuticals
Bio-Thera Solutions
BioArctic
Biogen
BridgeBio Pharma
Daiichi Sankyo
Eisai
JNJ
Madrigal Pharmaceuticals
Merck
Sutro BioPharma
Tasly Pharmaceutical Group
Flag link:
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA
Fierce Biotech
Biogen
Eisai
lecanemab
FDA
Aduhelm
fast track
Alzheimer's disease
Flag link:
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators
Fierce Pharma
Biogen
Eisai
Aduhelm
Japan
Alzheimer's disease
Flag link:
Licensing deals rack up in 2021
Licensing deals rack up in 2021
EP Vantage
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
Flag link:
Eisai-Biogen Alzheimer's Drug Shows Amyloid Reduction, Disease-Modifying Effect
Eisai-Biogen Alzheimer's Drug Shows Amyloid Reduction, Disease-Modifying Effect
BioSpace
Eisai
Biogen
lecanemab
Alzheimer's disease
clinical trials
Flag link:
What Novartis could buy with its windfall
What Novartis could buy with its windfall
EP Vantage
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Flag link:
Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s
Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s
Pharmaforum
Altoida
Eisai
clinical trials
augmented reality
Alzheimer's disease
Flag link:
Seizing Aduhelm precedent, Biogen, Eisai get the ball rolling on another accelerated Alzheimer's approval
Seizing Aduhelm precedent, Biogen, Eisai get the ball rolling on another accelerated Alzheimer's approval
Endpoints
Biogen
Aduhelm
Eisai
Alzheimer's disease
FDA
lecanemab
Flag link:
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
BioSpace
FDA
Cara Therapeutics
Vifor Pharma
Korsuva
Kadmon
belumosudil
Bristol Myers Squibb
Opdivo
Merck
Eisai
Keytruda
Flag link:
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Merck
Keytruda
advanced renal cell carcinoma
renal cell carcinoma
Eisai
Lemvima
FDA
Flag link:
Biogen, Eisai are pushing for another accelerated Alzheimer's OK — this time for BAN2401
Biogen, Eisai are pushing for another accelerated Alzheimer's OK — this time for BAN2401
Endpoints
Biogen
Eisai
FDA
Alzheimer's disease
BAN2401
Flag link:
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Bloomberg
Biogen
Eisai
Alzheimer's disease
lecanemab
BAN2401
Flag link:
Eisai-Biogen Alzheimer’s drug gets FDA breakthrough designation
Eisai-Biogen Alzheimer’s drug gets FDA breakthrough designation
Pharmaceutical Business Review
Eisai
Biogen
FDA
lecanemab
breakthrough status
Alzheimer's disease
Flag link:
Bristol Myers pays $650M for rights to Eisai's phase 1 ADC
Bristol Myers pays $650M for rights to Eisai's phase 1 ADC
Fierce Biotech
Bristol Myers Squibb
antibody-drug conjugate
MORAb-202
Eisai
Flag link:
Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate
Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate
Reuters
Bristol Myers Squibb
Eisai
drug development
cancer
Flag link:
When Will Lecanemab be Available to Alzheimer’s Patients?
When Will Lecanemab be Available to Alzheimer’s Patients?
BioSpace
Eisai
lecanemab
BAN2401
Alzheimer's disease
Flag link:
Biogen's Aducanumab: A Look at the Drug’s History and Recent Updates
Biogen's Aducanumab: A Look at the Drug’s History and Recent Updates
BioSpace
Biogen
Eisai
aducanumab
Alzheimer's disease
Flag link:

Pages